Underwriting AgreementUnderwriting Agreement • August 21st, 2020 • ELI LILLY & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $850,000,000 in aggregate principal amount of its 2.500% Notes due 2060 (the “2060 Notes”) and $250,000,000 in aggregate principal amount of its 2.250% Notes due 2050 (the “New 2050 Notes” and, together with the 2060 Notes, the “Securities”), in each case on the terms set forth in Schedule 2 hereto. The Securities will be issued pursuant to an Indenture, dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”), between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
